PUBLISHER: Grand View Research | PRODUCT CODE: 1609950
PUBLISHER: Grand View Research | PRODUCT CODE: 1609950
The global pain management devices market size is expected to reach USD 13.16 billion in 2030 and is expected to grow at a CAGR of 9.4% from 2025 to 2030. The market is experiencing growth due to the rising prevalence of chronic diseases and the expanding elderly population worldwide. The preference for pain management devices as an alternative to surgical procedures and oral medications is also expected to drive market growth significantly. Technological advancements in the field, particularly in electrostimulation devices, incorporating Artificial Intelligence (AI), Microelectromechanical Systems (MEMS), and Machine Learning(ML) applications are contributing to the market growth.
Furthermore, there is a rising incidence of musculoskeletal disorders, including osteoarthritis, arthritis, rheumatoid arthritis, and degenerative orthopedic conditions. This rise in cases has led to an increased impact on individuals' ability to perform daily activities and a higher prevalence of chronic pain among this population. For instance, according to the Global RA Network, over 350 million individuals had arthritis worldwide in 2021. Furthermore, technological advancements are anticipated to drive further growth. For instance, in October 2022, Nevro Corp., a medical device organization, revealed that it had obtained permission from the FDA, a federal agency of the Department of Health and Human Services, for the Senza HFX iQ Spinal Cord Stimulation (SCS) system.
It is a system that utilizes Artificial Intelligence (AI) to maintain and optimize pain alleviation by utilizing each patient's response. This would significantly expand the company's portfolio. Moreover, the company started the U.S. full market launch of the SCS system in March 2023. Many elective surgeries were canceled or postponed during the COVID-19 pandemic to reduce the exposure of the patients as well as the healthcare providers, which is anticipated to augment the need for pain management devices. In July 2020, the U.S. Food and Drugs Authority permitted an Emergency Use Authorization (EUA) for the electroCore- a non-invasive vagus nerve stimulator to help COVID-19 patients at home with asthma-related problems.